31 Jul Fractyl Health
Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer
Oct. 7 | 10:15am | FLW Ballroom F
Burlington, Massachusetts
(NASDAQ: GUTS)
Fractyl Health is a metabolic therapeutics company pioneering pattern-breaking treatments for obesity and type 2 diabetes (T2D), with the goal of transforming metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. RJVA-001, a candidate from Fractyl’s Rejuva gene therapy platform, is delivered via an endoscopic ultrasound-guided infusion into the pancreas. The construct is designed to express glucagon-like peptide-1 (GLP-1) locally in beta cells using nutrient-responsive control, potentially enabling physiologic hormone secretion without the high circulating levels that contribute to side effects seen with systemic GLP-1 therapy. This distinction opens the door to efficacy that matches or exceeds drugs with potentially superior tolerability profiles due to low circulating levels of drug. Fractyl Health submitted the first Clinical Trial Application (CTA) module to regulators and, if authorized, expects to dose T2D patients and report preliminary data in 2026.
